Awaiting development: Guidance and quality standards

Skip to filters Skip to results

Showing 251 to 275 of 391

Guidance and quality standards awaiting development
Title	Type
Povorcitinib for treating prurigo nodularis [TSID12385]	Technology appraisal guidance
Pozelimab with cemdisiran for treating symptomatic generalised myasthenia gravis [ID6720]	Technology appraisal guidance
Prevention of dementia	Quality standard
Pridopidine for treating Huntington's disease [ID6525]	Technology appraisal guidance
Primary hyperparathyroidism	Quality standard
Procalcitonin to guide decisions on stopping antibiotics in people with confirmed or highly suspected sepsis	HealthTech guidance
ProKnow cloud-based system for radiotherapy data storage, communication and management	HealthTech guidance
Prostate cancer (hormone relapsed, homologous recombination deficiency, metastatic) – rucaparib (after 1 therapy) [ID6127]	Technology appraisal guidance
PXT3003 for treating Charcot-Marie-Tooth disease type 1A in people aged 16 and over [ID1439]	Technology appraisal guidance
Radium-223 dichloride with enzalutamide for treating asymptomatic or mildly symptomatic hormone-relapsed metastatic prostate cancer with bone metastases [ID6512]	Technology appraisal guidance
Ranibizumab port delivery system for treating diabetic macular oedema [ID6137]	Technology appraisal guidance
Ravulizumab for preventing kidney events in people with chronic kidney disease at high risk after a cardiopulmonary bypass [ID6632]	Technology appraisal guidance
Ravulizumab for treating primary IgA nephropathy [ID6703]	Technology appraisal guidance
Ravulizumab for untreated thrombotic microangiopathy after a haematopoietic stem cell transplant in people aged 28 days and over [TSID10642][ID6319]	Technology appraisal guidance
Readmission to ICU within 48hrs	Quality standard
Reinforcement of a permanent stoma with synthetic or biological mesh to prevent a parastomal hernia	HealthTech guidance
Remdesivir for treating COVID 19 [ID3808]	Technology appraisal guidance
Remibrutinib for treating chronic inducible urticaria inadequately controlled by H1-antihistamines [ID6742]	Technology appraisal guidance
Remibrutinib for treating chronic spontaneous urticaria inadequately controlled by H1-antihistamines in people 12 to 17 years [ID6649]	Technology appraisal guidance
Retatrutide for managing overweight and obesity [ID6644]	Technology appraisal guidance
Retifanlimab with chemotherapy for previously untreated metastatic non-small-cell lung cancer [ID6436]	Technology appraisal guidance
Riliprubart for treating chronic inflammatory demyelinating polyneuropathy [TSID12314]	Technology appraisal guidance
Ritlecitinib for treating non-segmental vitiligo in people 12 years and over [ID6584]	Technology appraisal guidance
Rivaroxaban for treating chronic heart failure [ID1462]	Technology appraisal guidance
Rivoceranib for treating unresectable or advanced gastric or gastro-oesophageal junction cancer after 2 or more therapies [ID3819]	Technology appraisal guidance

Results per page

10
25
50
All